Epigenetica e cancro del colon-retto: limiti e prospettive

L’Osservatorio

Epigenetics of colorectal cancer: drawbacks and perspectives

Summary

Colorectal cancer (CRC) is one of the most common cancers worldwide and the second leading cause of cancer-related mortality. The current screening strategies, albeit effective for improving clinical outcomes, are still plagued by poor adherence rate, especially in western countries. An increasing number of studies is hence focusing on identification of innovative circulating biomarkers. CRC develops from early premalignant lesions to full blown cancer via a multi-step process, involving a kaleidoscope of genetic mutations accumulating over time. Recent improvements of our understanding of CRC biology, coupled with notable advances in molecular technologies, have led to identify a number of epigenetic alterations involved in colorectal carcinogenesis. These essentially include epigenetic marks, the best characterized of which is hypermethylation of DNA promoters. To date, many studies have convincingly demonstrated the existence of an association between methylation status of certain genes and risk of cancer, thus supporting its possible assessment as a new putative biomarker. Although increasing efforts have been placed for validating methylation assays in serum or plasma specimens, many aspects remains challenging, such as the large number of factors modulating concordance between tissues and plasma methylation profiles. Only a complete understanding of all aspects influencing the possibility to detect epigenetic abnormalities in the bloodstream will permit achieving the goal of translating the so-called liquid biopsy from basic research into clinical practice.

Keywords

Colorectal cancer Epigenetics Promoter methylation SEPT9 

Notes

Conflitti di interesse

Nessuno.

Studi condotti su esseri umani e animali

Non applicabile.

Bibliografia

  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30 CrossRefPubMedGoogle Scholar
  2. 2.
    Osservatorio Nazionale Screening. Lo screening colorettale. https://www.osservatorionazionalescreening.it/content/lo-screening-colorettale (Accesso 5 gennaio 2018)
  3. 3.
    Danese E, Montagnana M (2017) Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers. Ann Transl Med 5:279 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tse JWT, Jenkins LJ, Chionh F et al. (2017) Aberrant DNA methylation in colorectal cancer: what should we target? Trends Cancer 3:698–712 CrossRefPubMedGoogle Scholar
  6. 6.
    Walther A, Johnstone E, Swanton C et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9:489–499 CrossRefPubMedGoogle Scholar
  7. 7.
    Danese E, Minicozzi AM, Benati M et al. (2013) Epigenetic alteration: new insights moving from tissue to plasma—the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer 109:807–813 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Molnár B, Tóth K, Barták BK et al. (2015) Plasma methylated septin 9: a colorectal cancer screening marker. Expert Rev Mol Diagn 15:171–184 CrossRefPubMedGoogle Scholar
  9. 9.
    Danese E, Minicozzi AM, Benati M et al. (2015) Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. PLoS ONE 10:e0126417 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tóth K, Wasserkort R, Sipos F et al. (2014) Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS ONE 9:e115415 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    He Q, Chen HY, Bai EQ et al. (2010) Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet 202:1–10 CrossRefPubMedGoogle Scholar
  12. 12.
    Rex DK, Boland CR, Dominitz JA et al. (2017) Colorectal cancer screening: recommendations for physicians and patients from the US multi-society task force on colorectal cancer. Gastroenterology 153:307–323 CrossRefPubMedGoogle Scholar
  13. 13.
    Bibbins-Domingo K, Grossman DC, Curry SJ et al. (2016) Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 315:2564–2575 CrossRefPubMedGoogle Scholar

Copyright information

© Società Italiana di Patologia Clinica e Medicina di Laboratorio 2018

Authors and Affiliations

  1. 1.Sezione di Biochimica Clinica, Dipartimento di Neuroscienze, Biomedicina e MovimentoUniversità degli Studi di VeronaVeronaItalia

Personalised recommendations